Company Filing History:
3 out of 832,891 Years Active: 2001-2003
Title: Edward Giovannucci: Innovator in Prostate Cancer Research
Introduction
Edward Giovannucci is a notable inventor based in Wakefield, MA (US). He has made significant contributions to the field of prostate cancer research, holding a total of 3 patents. His work focuses on the relationship between insulin-like growth factors and prostate cancer risk.
Latest Patents
Giovannucci's latest patents include methods for predicting the propensity to develop prostate cancer. These methods involve measuring the insulin-like growth factor (IGF) status of individuals. It has been established that individuals with high IGF status, compared to normal reference range values, are at an increased risk for developing prostate cancer. Specifically, the IGF status can be determined by measuring IGF-I levels and/or insulin-like growth factor binding protein-3 (IGFBP-3) levels. High IGF levels combined with low IGFBP levels indicate a high IGF status. Furthermore, a method for determining the prognosis of existing prostate cancers or monitoring disease progression involves assessing the IGF/PSA status of an individual. Those with a high IGF/PSA status, characterized by both high IGF and high PSA levels, tend to develop severe prostate cancer and have a poorer overall prognosis.
Career Highlights
Throughout his career, Edward Giovannucci has focused on advancing the understanding of prostate cancer and its risk factors. His innovative approaches have contributed to the development of predictive methods that can aid in early detection and treatment strategies.
Collaborations
Giovannucci has collaborated with esteemed colleagues, including Michael N Pollak and Meir J Stampfer. These partnerships have further enhanced the impact of his research in the medical community.
Conclusion
Edward Giovannucci's work in the field of prostate cancer research exemplifies the importance of innovation in medical science. His patents and research efforts continue to pave the way for improved understanding and management of prostate cancer risk.